Marin Bay Wealth Advisors LLC Sells 5,723 Shares of AbbVie Inc. $ABBV

Marin Bay Wealth Advisors LLC trimmed its position in AbbVie Inc. (NYSE:ABBV) by 67.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,784 shares of the company’s stock after selling 5,723 shares during the quarter. Marin Bay Wealth Advisors LLC’s holdings in AbbVie were worth $728,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Americana Partners LLC lifted its stake in AbbVie by 0.5% in the third quarter. Americana Partners LLC now owns 268,612 shares of the company’s stock valued at $70,266,000 after buying an additional 1,313 shares during the period. Aprio Wealth Management LLC grew its position in shares of AbbVie by 15.2% during the 3rd quarter. Aprio Wealth Management LLC now owns 12,020 shares of the company’s stock worth $3,144,000 after buying an additional 1,590 shares during the period. Fusion Capital LLC grew its position in shares of AbbVie by 3.9% during the 3rd quarter. Fusion Capital LLC now owns 37,545 shares of the company’s stock worth $9,821,000 after buying an additional 1,393 shares during the period. LJI Wealth Management LLC increased its stake in shares of AbbVie by 10.8% in the 3rd quarter. LJI Wealth Management LLC now owns 2,046 shares of the company’s stock valued at $535,000 after acquiring an additional 200 shares during the last quarter. Finally, Modera Wealth Management LLC increased its stake in shares of AbbVie by 9.7% in the 3rd quarter. Modera Wealth Management LLC now owns 85,867 shares of the company’s stock valued at $22,462,000 after acquiring an additional 7,590 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ABBV. Scotiabank increased their price target on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. Bank of America restated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their target price for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Finally, Piper Sandler increased their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $279.86.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

AbbVie Trading Up 1.4%

NYSE:ABBV opened at $294.80 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $298.74. The stock has a market cap of $520.85 billion, a price-to-earnings ratio of 50.74, a PEG ratio of 1.35 and a beta of 0.24. The stock has a 50-day moving average price of $269.35 and a two-hundred day moving average price of $237.23.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.86 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.